The Motor Imagery Based on Action Observation Treatment on Dysphagia in Wallenberg Syndrome
Launched by LE WANG · Jan 17, 2024
Trial Information
Current as of July 03, 2025
Completed
Keywords
ClinConnect Summary
The goal of this clinical trial is to learn about on dysphagia in wallenberg syndrome. The main questions it aims to answer are:
* the efficacy of motor imagery based on action observation treatment in the rehabilitation of patients with dysphagia in Wallenberg syndrome.
* apply functional near infrared spectroscopy to explore the mechanism of action of this therapy.
Both groups received conventional dysphagia treatment, and the experimental group underwent the addition of motor imagery based on action observation treatment to the control group once a day for 14 days. Overall swallowing f...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age ranged from 18-80 years and right-handed;
- • first onset, vital signs stable and conscious;
- • the dysphagia confirmed by videofluoroscopic swallowing study;
- • no cognitive impairment, the mini-mental state examination score: \>17 for those with an illiterate education, \>20 for those with an elementary education, and \>24 for those with a secondary education and above;
- • good motor imagery ability with kinesthetic and visual imagery questionnaire-10 score ≥25;
- • cranial integrity without craniotomy and/or craniectomy;
- • patient and/or his/her relative agrees and signs written informed consent.
- Exclusion Criteria:
- • combined ischemic foci at other sites;
- • presence of organic swallowing dysfunction or pre-existing dysphagia due to Parkinson's disease, dementia, and others;
- • severe cardiac, pulmonary, hepatic, and renal insufficiency and vital organ failure;
- • significant psychological disorders such as anxiety and depression;
- • infected or broken skin on the head;
- • poorly controlled epilepsy;
- • poor patient compliance.
About Le Wang
Le Wang is a dedicated clinical trial sponsor committed to advancing medical research through innovative and rigorous study designs. With a focus on improving patient outcomes, Le Wang collaborates with healthcare professionals and organizations to conduct high-quality clinical trials across various therapeutic areas. The organization emphasizes adherence to ethical standards and regulatory compliance, ensuring the safety and well-being of participants while generating valuable data that contributes to the development of new treatments. Leveraging a team of experienced researchers and a robust network, Le Wang strives to address unmet medical needs and drive progress in the healthcare field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhengzhou, Henan, China
Zhengzhou, Henan, China
Patients applied
Trial Officials
Xi Zeng
Study Director
The First Affiliated Hospital of Zhengzhou University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported